• Who are we?
    • Our history
    • Board of Directors
    • The Management committee and scientific leadership
    • Our scientific advisory board
  • Our research teams
    • Our research teams and our platforms
      • Progressive muscular dystrophies
      • Neuromuscular diseases and gene therapy
      • Gene Editing
      • Immunology and liver diseases
      • DNA Bank
      • Genethon’s Imaging Cytometry Platform
    • Gene Editing
    • Bioproduction
    • Understanding gene therapy
    • Immunology of gene transfer: a crucial issue
  • Our pipeline
    • Duchenne muscular dystrophy
    • Infant Spinal muscular atrophy
    • SMA-PME and Farber’s disease
    • Myotubular myopathy
    • Limb girdle muscular dystrophies
    • Wiskott-Aldrich syndrome
    • Fanconi’s anemia
    • Sickle cell disease
    • Chronic septic granulomatosis
    • Severe Combined Immunodefiency (SCID)
    • Cori Forbes disease
    • GSD1a – Glygogen Storage Disease Type 1a
    • Crigler-Najjar syndrome
    • Pompe disease
    • Leber Hereditary Optic Neuropathy
  • Our partners
  • Our commitment
    • Access to treatments
    • Why work at Genethon?
    • Tours of Genethon
    • 1,000 researchers initiative
    • The DNA School
  • Newsroom
    • News
    • Press Releases
    • Newsletter
    • Publications
Contact Join us
FR
EN

Author: admin

On the Internet site of the Usine Nouvelle magazine you can discover the Genethon laboratory financed by donations to the Telethon through images from behind the scenes

September 1, 2011

Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial

July 21, 2011

Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial

March 8, 2011

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

January 5, 2011

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

December 14, 2010

Thérapie génique – la découverte d’un mini-gène fonctionnel ouvre une nouvelle voie thérapeutique dans les dysferlinopathies

September 22, 2010

Innovative biotherapies and genetic eye diseases

June 3, 2010

Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

February 24, 2010

Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive

February 23, 2010

Journée internationale Maladies Rares du 28 février 2010 : Les acteurs de la Plateforme Maladies Rares attendent un second plan français à la hauteur de enjeux

February 18, 2010

Posts navigation

Older posts
Newer posts
Contact Join us Personal data protection policy

Genethon is a member of the Biotherapies Institute for Rare Diseases that was created by AFM-Telethon

AFM-Téléthon
Biotherapies Institute
Genethon
Institute of Myology
I-Stem
En cliquant sur « Tout accepter », vous consentez au dépôt de cookies sur votre appareil pour améliorer votre navigation sur le site, mesurer les performances du site, personnaliser le contenu ou la publicité affichée sur le site et d’autres sites. Votre consentement est valable 6 mois. Vous pouvez personnaliser vos choix ou retirer votre consentement à tout moment en cliquant sur le lien « Gérer mes cookies ». Pour plus d’information, et notamment pour consulter la liste des tiers intervenant sur notre site, consultez la Politique de cookies accessible en bas de page.
Manage my cookies Deny all cookies Accept all
Manage consent

Manage consent

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo